Brain proteins could amplify GLP-1 drug effectiveness fivefold, U-M study finds

Researchers at the University of Michigan have identified a potential way to supercharge some of the most talked-about drugs in medicine right now. In a study published this week in the Journal of Clinical Investigation, they found that two brain proteins—melanocortin 3 and melanocortin 4—could be manipulated to make GLP-1 drugs like Ozempic and Mounjaro work up to five times more effectively, while simultaneously reducing the nausea and other side effects that plague many patients.

The discovery centers on how the brain regulates hunger and energy. These melanocortin proteins sit on the surface of neurons deep in the brain and act as a kind of master control system for feeding behavior. They process signals about long-term energy reserves—how much fat you have stored—and short-term fullness cues that arrive from the gut. Roger Cone, a physiologist at Michigan who led the work, describes them as fundamental to how the body knows when to eat and when to stop. The question his team asked was straightforward: what happens if you prime this melanocortin system before giving someone a GLP-1 drug?

GLP-1 agonists work by mimicking a hormone the gut naturally releases when it's full, essentially tricking the brain into thinking the body has eaten enough. They've become famous for treating not just type 2 diabetes but also obesity, heart disease, and possibly addiction. But they come with drawbacks. Some patients experience severe nausea. Others don't respond as well as hoped. Cone's team wondered whether activating the melanocortin system first might amplify the drug's desired effects while leaving the side effects behind.

Working in mice, the researchers tested what happened when they either blocked one melanocortin protein (MC3R) or boosted another (MC4R). Because MC3R naturally suppresses MC4R, these two approaches produced similar results. When they combined these manipulations with GLP-1 drugs, the effect was striking. Mice showed up to five times more weight loss and ate significantly less than mice receiving only the GLP-1 drug alone. Critically, when the researchers measured brain activity in regions associated with nausea, they found no increase in activation when the melanocortin system was primed. Instead, the combination dramatically increased activity in the brain's feeding control centers—exactly where you'd want the drug to work harder.

Naima Dahir, the study's first author and a postdoctoral fellow in Cone's lab, and her colleagues tested this approach against multiple hormones that suppress appetite, not just GLP-1 drugs. Every time, the same pattern emerged: priming the melanocortin system made animals hypersensitive to anti-feeding signals across the board. The implication is significant. A patient who experiences unbearable side effects from a standard GLP-1 dose might tolerate a much lower dose if it were paired with an MC4R agonist—and still see better results than they would have at the higher dose alone. Alternatively, patients who haven't responded adequately to existing medications might finally see meaningful improvement.

The work remains preliminary. Everything described here happened in mouse brains, not human ones. But Cone notes that the melanocortin system is highly conserved across species—meaning it works essentially the same way in humans as it does in the rodents his team studied. Decades of research on these proteins in mice has consistently translated to human biology. Before any of this reaches patients, though, drug developers will need to create compounds that safely target MC4R in the human brain and then run clinical trials to confirm the findings hold up in real people. The National Institutes of Health and Courage Therapeutics funded this research, and the latter company's involvement suggests commercial interest in pursuing this angle. The path from mouse model to pharmacy shelf is long, but this study has mapped out a promising direction.